BTBabafemi Taiwo

Babafemi Taiwo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Babafemi Taiwo has a total of 249 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    iTRAIN During iCARE Nigeria: Virtual Implementation Research Training Course Nested Within an Ongoing Trial

    by Kehinde M. Kuti, Aima A. Ahonkhai, Bibilola Oladeji, Sarah Zechariah, Chibueze Adirieje, Temitope Omotosho, Olayinka Omigbodun, Nadia A. Sam-Agudu, Lisa M. Kuhns, Robert Garofalo, et al.

    Background HIV clinicians and program implementers in Nigeria have limited implementation research training opportunities. We developed a virtual implementation research training program (iTRAIN) for clinicians and HIV program staff implementing the Intensive Combination Approach to Roll Back the Epidemic in Nigerian Adolescents (iCARE Nigeria) study. Methods iTRAIN was developed and facilitated by iCARE Nigeria investigators from Nigeria and the United States with extensive implementation research experience. The nine-session online course covered core principles of implementation research. incorporating developing a relevant concept note embedded into iCARE. Between September 2021–2022, content was delivered through asynchronous pre-recorded lectures and readings, followed by facilitator-led synchronous sessions. All six study site teams were assigned a course facilitator for mentoring to develop implementation research proposals nested in the iCARE study. We conducted pre- and post-training surveys to evaluate iTRAIN using the Kirkpatrick Framework and conducted analysis using explanatory mixed methods. Findings We enrolled 42 participants (55% male, 48% clinicians), with 50% of enrollees reporting no IR experience. Completion rate was 95%; 79% of participants rated the course overall as “excellent”, and 79% reported that their goal of gaining implementation research knowledge were met “a lot”. IR knowledge increased “a lot” in 71%, and 97% would “probably or definitely” use their iTRAIN knowledge in future research. All six sites developed implementation research concept notes addressing topics relevant to iCARE Nigeria, with four implemented. Conclusion iTRAIN represents a successful embedded implementation research virtual training and mentoring program which resulted in increased participant knowledge and capacity. Our training model can serve as a blueprint for study-embedded implementation research capacity-building in Nigeria and similar settings.

  • Open Access

    Exploratory Impact of iCARE Nigeria, a combined mHealth and Peer Navigation Intervention, on Depressive Symptoms and Substance Use Among Youth Living With HIV In Nigeria: a single-arm trial (Preprint)

    by Olusegun Ayomikun Ogunmola, Rita Frinue Tamambang, Kehinde Kuti, Lisa Kuhns, Olutosin Awolude, Adedotun Adetunji, Bibilola Oladeji, Oladayo Olaleye, Adeola Mary Oyerinde, Robert Garofalo, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Mental health problems are a barrier to the wellbeing of youth living with HIV (YLWH). Many YLWH in Nigeria face peculiar bio-psycho-social vulnerabilities that predispose them to mental health problems including depression and substance use. In addition to improving treatment outcomes like medication adherence and linkage to care, peer engagement has shown some promise in improving the social and emotional wellbeing of this population. Mobile health (mHealth) interventions like SMS medication reminders may also contribute to better outcomes in YLWH. Emerging evidence suggests that combination interventions may be more effective than single interventions in improving key HIV testing and treatment outcomes among youth in Nigeria. Objective: To explore the impact of Intensive Combination Approach to Rollback the Epidemic in Nigerian Adolescents (iCARE Nigeria) study— an mHealth+peer navigation intervention primarily aimed at medication adherence and viral suppression— on depressive symptoms and substance use among YLWH in Nigeria Methods: A single-arm clinical trial was conducted at the Infectious Disease Institute (IDI), College of Medicine, University of Ibadan, Nigeria— primarily to improve medication adherence and viral suppression among YLWH attending its HIV clinic. The intervention combined peer navigation and daily, two-way, text message medication reminders delivered over a period of 48 weeks. Participants were screened at baseline and follow-up visits (24 and 48 weeks) for depression and substance use using standardized measures. Paired t-tests and McNemar’s tests were used to investigate the change in depressive symptoms and the change in the proportion of participants reporting substance use over time, respectively. Results: All 40 enrolled participants (50% male; mean age 19.9, SD 2.5 years) completed baseline and follow-up visits at week 24, while 37 (92.5%) participants completed the week 48 visit. Compared with baseline, there were significantly fewer self-reported depressive symptoms observed at 48 weeks (M= 2.89 vs 2.08, t36=2.04, 95%CI=0.006-1.615) but not at 24 weeks (M= 2.28 vs 2.62, t36=0.47, 95%CI=-0.742-1.442). There were fewer self-reports of substance use at weeks 24 and 48 when compared to baseline, but these were not statistically significant (OR=∞, 95%CI= 0.189-∞ and OR= 3.0, 95%CI=0.241-157.492 respectively). Conclusions: These findings suggest a statistically significant reduction in depressive symptoms among YLWH over the 48-week intervention period that may be due to the iCARE Nigeria intervention. However, given limitations such as low levels of depressive symptoms at baseline, small sample size, and the lack of a control group, future studies such as the randomised stepped wedge evaluation of the iCARE intervention are needed to provide better insights into these exploratory findings.


  • Open Access

    Brief Report: Intracellular Cystatin B Levels Are Altered in HIV-Infected Participants With Respect to Neurocognitive Status and Antiretroviral Therapy

    by Skye Bs Opsteen, David Bs Moylan, Babafemi O. Taiwo, Kevin R. Robertson, E. Turner Overton, Gary R. Cutter, Steffanie Sabbaj, Sonya L. Heath, John J. Shacka

    With advances in HIV treatment, people with HIV (PWH) are living longer but experience aging-related comorbidities, including cognitive deficits, at higher rates than the general population. Previous studies have shown alterations in lysosomal proteins in blood from PWH with severe dementia. However, these markers have not been evaluated in PWH with milder neurocognitive impairment. We sought to determine whether levels of the lysosomal cysteine protease cathepsin B (CatB) and its endogenous inhibitor cystatin B (CysB) were altered in PWH with neurocognitive impairment and whether antiretroviral therapy (ART) further influenced these levels. Peripheral blood mononuclear cells were obtained from the tenofovir arm of a multicenter clinical trial in which ART-naive, HIV+ participants received treatment for 48 weeks (ACTG A5303, NCT01400412). PWH were divided by neurocognitive status (eg, with or without neurocognitive impairment) before ART initiation. Intracellular levels of CatB and CysB were measured in T cells and monocytes by means of flow cytometry. Levels of CysB were significantly decreased in both CD4+ T cells and CD8+ T cells after 48 weeks of ART in HIV+ participants without neurocognitive impairment but not in participants with neurocognitive impairment. Levels of CysB were increased in CD14+ monocytes from the participants with neurocognitive impairment after ART. Levels of CysB and CatB positively correlated regardless of HIV, neurocognitive status, or exposure to ART. These findings suggest that CysB has the potential to provide mechanistic insight into HIV-associated neurocognitive disorders or provide a molecular target for systemic monitoring or treatment of neurocognitive impairment in the context of ART and should be investigated further.

  • Open Access

    Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19

    by Davey M. Smith, Jonathan Z. Li, Carlee Moser, Eunice Yeh, Judith S. Currier, Kara W. Chew, Michael D. Hughes, ACTIV-2/A5401 Study Team, Eric Daar, David Wohl, et al.

    Recurrence of symptoms after finishing treatment for COVID-19 with nirmatrelvir-ritonavir (Paxlovid) has become increasingly recognized.1-3 The biological underpinning of this phenomenon is unclear, and its etiology may be multifactorial, including rapid clearance of nirmatrelvir coupled with delayed immune responses or possible development of drug resistance.1-3 The contribution of treatment to symptom rebound needs to be differentiated from symptom rebound that might occur during the natural history of COVID-19. In this cohort study, we sought to determine how often COVID-19 symptoms recurred when the disease was untreated.


  • Open Access

    877. North American Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes

    by Babafemi O Taiwo, Darrell Tan, Parul Patel, Paula Teichner, Joseph Polli, Louise Garside, Ronald D’aMico, Christine L Talarico, Rodica Van Solingen-Ristea, Bryan Baugh, et al.

    Cabotegravir (CAB) plus rilpivirine (RPV) is the first complete long-acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. CAB+RPV LA dosed every 4 weeks (Q4W) or every 8 weeks (Q8W) demonstrated noninferior efficacy in multinational Phase 3/3b trials. This post hoc descriptive analysis summarizes efficacy, virologic outcomes, safety, and treatment preference for US and Canadian (CAN) participants through Week (W) 48. This analysis focuses on data for US/CAN participants naive to CAB+RPV (n=376) from the larger pooled population of the ATLAS, FLAIR, and ATLAS-2M Phase 3/3b studies (N=1245). Endpoints included the proportion of participants with plasma HIV-1 RNA ≥ 50 and < 50 c/mL at W48 (FDA Snapshot algorithm), incidence of confirmed virologic failure (CVF; 2 consecutive HIV-1 RNA ≥ 200 c/mL), safety, and treatment preference through W48. 376 US/CAN participants received CAB+RPV LA Q4W or Q8W. Median (range) age was 39y (20–74); 14.9% were female, 66.0% were White. At W48, 93.1% (350/376) maintained virologic suppression (HIV-1 RNA < 50 c/mL), 1.9% (7/376) had HIV-1 RNA ≥ 50 c/mL, and 0.8% (3/376) met the CVF criterion, consistent with the overall global pooled population (Table 1). Two of the three participants with CVF had ≥ 2 of the three baseline factors (archived RPV resistance-associated mutations [RAMs], HIV subtype A6/A1, body mass index [BMI] ≥ 30 kg/m2) previously associated with CVF. Among the US/CAN participants with a single baseline factor, none met CVF. Overall, archived RPV RAMs were observed in 3.2% (12/376), HIV subtype A6/A1 in 1.1% (4/376), and BMI ≥ 30 kg/m2 in 26.3% (99/376) of participants. Safety and injection site reaction findings were similar to the overall pooled population (Table 2). Most participants (120/134, 89.6%) preferred LA over oral dosing (7/134, 5.2%). Table 1. Snapshot outcomes following CAB+RPV LA Q4W and Q8W at Week 48 in participants naive to CAB+RPV from ATLAS, FLAIR, and ATLAS-2M (ITT-E population) Table 2. Safety summary through Week 48 following CAB+RPV LA Q4W and Q8W or comparator ART in participants naive to CAB+RPV from ATLAS, FLAIR, and ATLAS-2M In US/CAN Phase 3/3b trial participants, CAB+RPV LA was highly effective and well tolerated, with outcomes consistent with the overall pooled population. Baseline prevalence of archived RPV RAMs and subtype A6/A1 was low and aligned with regional prevalence/surveillance data. CAB+RPV LA provides a tolerable and effective injectable LA treatment option for virologically suppressed US/CAN individuals with HIV. Babafemi O. Taiwo, MBBS, Gilead (Consultant)Merck (Consultant)ViiV Healthcare (Consultant) Darrell Tan, MD PhD, Abbvie (Grant/Research Support)Gilead (Grant/Research Support)GlaxoSmithKline (Scientific Research Study Investigator)ViiV Healthcare (Grant/Research Support) Parul Patel, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Paula Teichner, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Joseph Polli, PhD, FAAPS, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Louise Garside, PhD, GlaxoSmithKline (Employee) Ronald D’Amico, DO, MSc, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Christine L. Talarico, M.S., GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Rodica Van Solingen-Ristea, MD, Janssen Research and Development (Employee)ViiV Healthcare (Employee) Bryan Baugh, MD, Janssen, Johnson & Johnson (Employee, Shareholder) William Spreen, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Michael Aboud, MBChB, MRCP, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Matthew Bosse, DO, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)

  • Open Access

    Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria

    by Egon A. Ozer, Lacy M. Simons, Olubusuyi M. Adewumi, Adeola A. Fowotade, Ewean C. Omoruyi, Johnson A. Adeniji, Taylor J. Dean, Janet Zayas, Pavan P. Bhimalli, Michelle K. Ash, et al.

    The emergence of new SARS-CoV-2 variants with enhanced transmissibility or decreased susceptibility to immune responses is a major threat to global efforts to end the coronavirus disease 2019 (COVID-19) pandemic. Disparities in viral genomic surveillance capabilities and efforts have resulted in gaps in our understanding of the viral population dynamics across the globe. Nigeria, despite having the largest population of any nation in Africa, has had relatively little SARS-CoV-2 sequence data made publicly available. Here we report the whole-genome sequences of 74 SARS-CoV-2 isolates collected from individuals in Oyo State, Nigeria in January 2021. Most isolates belonged to either the B.1.1.7 Alpha “variant of concern” or the B.1.525 Eta lineage, which is currently considered a “variant of interest” containing multiple spike protein mutations previously associated with enhanced transmissibility and possible immune escape. Nigeria has the highest reported frequency of the B.1.525 lineage globally with phylogenetic characteristics consistent with a recent monophyletic origin and rapid expansion. Spike protein from the B.1.525 lineage displayed both increased infectivity and decreased neutralization by convalescent sera compared to Spike proteins from other clades. These results, along with indications that the virus is outpacing the B.1.1.7 lineage in Nigeria, suggest that the B.1.525 lineage represents another “variant of concern” and further underline the importance of genomic surveillance in undersampled regions across the globe.


  • Open Access

    Successful treatment of a Candida auris intra-articular infection

    by Scott C. Roberts, Teresa R. Zembower, Maureen K. Bolon, Anish R. Kadakia, Jasen H. Gilley, Jason H. Ko, Jessica Clark, Sharon Ward-Fore, Babafemi O. Taiwo

    A 78-year-old woman with a long-term ankle spacer with antibacterials developed an intra-articular Candida auris infection. Treatment with systemic antifungal therapy plus an amphotericin B moulded cement spacer was successful.


  • Open Access

    Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons

    by Robert A. Riestenberg, Andrew Furman, Avery Cowen, Anna Pawlowksi, Daniel Schneider, Alana A. Lewis, Sean Kelly, Babafemi Taiwo, Chad Achenbach, Frank Palella, et al.


  • Open Access

    The problem of resistance in Mycobacterium tuberculosis may be underestimated in Africa

    by Simeon I B. Cadmus, OlutayoI Falodun, ObaE Fagade, Robert Murphy, Babafemi Taiwo, Dick Van Soolingen

    Background: The true burden of tuberculosis (TB) and particularly multidrug-resistant (MDR) TB in Sub-Saharan Africa has remained underestimated. Methods: We investigated drug susceptibility profile and genetic diversity of Mycobacterium tuberculosis isolates collected from confirmed tuberculosis patients in Ibadan, southwestern Nigeria. Results: We confirmed that from 74 randomly selected Mycobacterium tuberculosis isolates available for drug susceptibility testing in Ibadan, in 2011, 13.5% of them were MDR-TB. Conclusions: This figure is obviously above the national and World Health Organization figures.


  • Open Access

    Phylogenetic Evidence of HIV-1 Sequence Evolution in Subjects with Persistent Low-Level Viraemia

    by Saran Vardhanabhuti, Babafemi Taiwo, Daniel R Kuritzkes, Joseph J Eron, Ronald J Bosch

    Background: Persistent low-level viraemia (LLV) during the treatment of antiretroviral therapy (ART) is associated with emergent drug resistance mutation (DRM); however, insight into its driver is limited. The objectives were to study HIV-1 pol sequence evolution in subjects with persistent LLV and evaluate factors associated with sequence changes. Methods: HIV-1 pol sequences from 54 treatment-naive subjects undergoing first-line lopinavir/ritonavir- or efavirenz-containing ART were obtained at pre-ART and end of LLV. HIV-1 sequence evolution was evaluated using phylogenetic analysis and Hamming distance calculation. DRMs were interpreted based on the International AIDS Society-USA 2011 update. Results: Subjects with new DRM during LLV had greater HIV-1 evolution across pol from the pre-ART to end of LLV compared with subjects without DRM. Evolution over non-DRM sites was similar between groups. Higher degree of genetic evolution was positively associated with higher HIV-1 RNA levels during LLV, both at DRM and non-DRM sites. Conclusions: The magnitude of LLV was the primary driver of evolution rate at DRM as well as non-DRM sites. Higher viral load was associated with DRM emergence in these subjects. These findings provide insights that may be applicable to the management of patients with persistent LLV during ART.